Company intelligence / Profile preview

TeraImmune

Gaithersburg, Maryland, United Statesteraimmune.com ↗

Ownership: Private
Development stage: Other

Overview

TeraImmune was a private biotech company focused on developing advanced regulatory T cell (Treg)-based cell therapies for autoimmune and immune-mediated diseases. Its lead candidate, TI-168, an autologous T cell receptor-engineered Treg therapy for hemophilia A with inhibitors, received FDA IND clearance and is in Phase 1/2a clinical trials. The company's proprietary platform technologies, TREGable™ and TREGing™, enabled both autologous and allogeneic Treg approaches, with additional preclinical programs for multiple sclerosis and atopic dermatitis. TeraImmune was acquired by Baudax Bio in June 2023.

Therapeutic areas: ImmunologyHematologyNeurologyDermatology
Modalities: Cell therapyAutologous T cell therapyAllogeneic T cell therapyRegulatory T cell (Treg) therapyT cell receptor-engineered T cell therapy
Industry: Biotech

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID)NIH/NIAID Cooperative Research and Development Agreement (CRADA)

Beyond the preview

Go deeper on TeraImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeraImmune.